H.I.G. Capital Closes Life Sciences Fund at $268M

Global private investment firm H.I.G. Capital, LLC has held the final close of its H.I.G. BioVentures II at $268m.

H.I.G. BioVentures II, L.P., which exceeded its $250m target, was raised from public and private pension funds, foundations, funds of funds, and large private family wealth managers.

Led by Managing Directors Aaron Davidson, Bruce Robertson, and Michael Wasserman, the fund will make venture capital investments in innovative, product development focused healthcare companies located throughout North America. It will seek opportunities in a broad range of sectors and development stages, with a focus on pharmaceuticals, medical devices, and diagnostics.



Join the discussion